Fig. 2.

a Flow cytometric analysis of the transfection efficiencies of control vector or CD36 overexpression (CD36OE) MKN45 cells. b Western blot analysis of the transfection efficiencies of control vector or CD36OE MKN45 cells. c Transwell migration and invasion assay of vector and CD36 OE MKN45 cells after 0.1 mM PA/50 μM or 100 μM etomoxir treatment in normoxia. d Transwell migration and invasion assay of vector and CD36 OE MKN45 cells after 0.1 mM PA/50 μM or 100 μM etomoxir treatment in hypoxia. e Rac1 and Cdc42 were measured using an Rac1/Cdc42 Activation Assay Kit. Vector and CD36OE MKN45 cells were subjected to 16 h fatty acid-free starvation and were then treated with etomoxir (100 μM) or 1% DMSO for 4 h, followed by exposure with PA (0.1 mM) or 3.75% ethanol in normoxia. PA palmitic acid